Loading clinical trials...
Loading clinical trials...
A Double-Blinded, Randomized, Placebo-Controlled, Phase 2B Trial of IMC-1 for the Treatment of Fibromyalgia
Conditions
Interventions
IMC-1
Placebo BID Tablet
Locations
42
United States
IMC Study Site
Birmingham, Alabama, United States
IMC Study Site
Rogers, Arkansas, United States
IMC Study Site
Oceanside, California, United States
IMC Study Site
Riverside, California, United States
IMC Study Site
Sacramento, California, United States
IMC Study Site
San Diego, California, United States
Start Date
June 3, 2021
Primary Completion Date
August 5, 2022
Completion Date
August 5, 2022
Last Updated
September 27, 2022
NCT05901259
NCT03759522
NCT07186751
NCT06574165
NCT06157866
NCT05067998
Lead Sponsor
Virios Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions